Related Experiment Video

Updated: May 22, 2026

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy

Helge Amthor1, Willem M H Hoogaars

  • 1Universite Pierre et Marie Curie, Institut de Myologie, Unite mixte de recherche UPMC-AIM UM 76, INSERM U 974, CNRS UMR 7215, 47-83, boulevard de l'Hopital, 75651 Paris Cedex 13, France. h.amthor@institut-myologie.org

Current Gene Therapy
|May 5, 2012
PubMed

Insights

Blocking myostatin/ActRIIB signaling shows promise for Duchenne muscular dystrophy (DMD) by improving muscle function in animal models. Further research is needed to understand molecular mechanisms and potential long-term effects.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • The myostatin/ActRIIB signaling pathway regulates skeletal muscle growth.
  • Abrogating this pathway has shown therapeutic potential in animal models of Duchenne muscular dystrophy (DMD).

Purpose of the Study:

  • To review current knowledge on myostatin/ActRIIB signaling.
  • To discuss its potential as a therapeutic target for DMD.
  • To highlight unresolved questions regarding its effects on muscle growth, regeneration, stem cell regulation, and metabolic alterations.

Main Methods:

  • Literature review of studies on myostatin/ActRIIB signaling.
  • Analysis of preclinical and clinical data on blockade strategies.
  • Discussion of current therapeutic approaches and their limitations.

Main Results:

  • Myostatin/ActRIIB blockade ameliorates pathology and function in dystrophic muscle models.
  • Therapeutic trials suggest feasibility of blockade strategies for clinical use.
  • Systemic blockade risks adverse effects due to interference with signaling in non-muscle tissues.

Conclusions:

  • Myostatin/ActRIIB signaling is a promising therapeutic target for DMD.
  • Further investigation is crucial to address unresolved questions regarding molecular mechanisms, muscle stem cell regulation, and metabolic effects.
  • Developing targeted strategies is essential to maximize benefits and minimize risks.

More Related Videos

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...